Compared with pGMLV-vector tumors (P = 0.013 at day 12, P = 0.006 at day 14, Fig. 5h), OX40 agonistic antibody exhibited an effective anti-tumor activity on pGMLV-miR130b tumors (P = 0.044 at day 12, P = 0.006 at day 14, Fig. 5h). This evidence concerns the gene TNFRSF4 and neoplasm.